Clinical Trials Browser

Withdrawn × INDUSTRY × Triple Negative Breast Neoplasms × Clear all

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03554109 2025-02-21

TNBC

Phase 2 Withdrawn

Breast

Triple Negative Breast Neoplasms

NCT05809895 2023-07-24

AdvanTIG-211

Phase 2 Withdrawn

Breast

Triple Negative Breast Neoplasms

NCT02201381 2022-07-18

METRICS

Phase 3 Withdrawn

BreastCNSGastrointestinalGynecologic

Brain Neoplasms, Breast Neoplasms, Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT05234606 2022-04-12

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Phase 1/2 Withdrawn

BreastGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Triple Negative Breast Neoplasms

NCT05008510 2022-02-08

VERU-111

Phase 2 Withdrawn

Breast

Triple Negative Breast Neoplasms

NCT03634150 2021-10-26

Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer

Phase 1/2 Withdrawn

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02161679 2021-08-19

Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer

Phase 2 Withdrawn

Breast

Triple Negative Breast Neoplasms

NCT04464967 2021-05-12

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Phase 1/2 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02685306 2017-03-09

A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

MK-5890-003

TNBC

AdvanTIG-211

METRICS

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

VERU-111

Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer

Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer